-
Gilead to acquire Kite Pharma
FOSTER CITY and SANTA MONICA, Calif. — In a deal estimated at roughly $11.9 billion, Gilead Sciences will be acquiring leading cell therapy company Kite Pharma for $180 per share, the companies announced last week. Among the potential treatments Gilead will acquire is Kite’s most advanced therapy candidate, axicaabtagene ciloleucel (axi-cel), a cancer-fighting therapy expected to be the first to market to treat refractory aggressive non-Hodgkin lymphoma, with a decision date of Nov. 29.
-
Turnaround efforts continue to generate 'positive momentum,' Fred's says
MEMPHIS, Tenn. — Fred’s on Friday posted a sales decline of 4.2% to $153 million for the four-week fiscal month ended Aug. 26. The decrease in total sales is related primarily to the closure of 39 underperforming stores in the first quarter, the company reported.